Development of an efficacious, semisynthetic glycoconjugate vaccine candidate against Streptococcus pneumoniae serotype 1
More about Open Access at the CrickAuthors list
Ben Schumann Katrin Reppe Paulina Kaplonek Annette Wahlbrink Chakkumkal Anish Martin Witzenrath Claney L Pereira Peter H SeebergerAbstract
Infections with Streptococcus pneumoniae are a major health burden. Glycoconjugate vaccines based on capsular polysaccharides (CPSs) successfully protect from infection, but not all pneumococcal serotypes are covered with equal potency. Marketed glycoconjugate vaccines induce low levels of functional antibodies against the highly invasive serotype 1 (ST1), presumably due to the obscuring of protective epitopes during chemical activation and conjugation to carrier proteins. Synthetic oligosaccharide antigens can be designed to carry linkers for site-selective protein conjugation while keeping protective epitopes intact. Here, we developed an efficacious semisynthetic ST1 glycoconjugate vaccine candidate. A panel of synthetic oligosaccharides served to reveal a critical role of the rare aminosugar, 2-acetamido-4-amino-2,4,6-trideoxy-d-galactose (d-AAT), for ST1 immune recognition. A monovalent ST1 trisaccharide carrying d-AAT at the nonreducing end induced a strong antibacterial immune response in rabbits and outperformed the ST1 component of the multivalent blockbuster vaccine Prevenar 13, paving the way for a more efficacious vaccine.
Journal details
Journal ACS Cent Sci
Volume 4
Issue number 3
Pages 357-361
Available online
Publication date
Keywords
Type of publication